semaj83/ctmatch_classification huggingface dataset:
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 20.0-60.0,  Autoimmune Thyroiditis Patients previously diagnosed with hypothyroidism induced by chronic autoimmune thyroiditis (CAT). The presence of hypothyroidism, laboratory measurements and ultrasonography were applied to diagnose CAT Significantly elevated concentrations of thyroid peroxidase (TPOAb) and/or thyroglobulin (TgAb) autoantibodies Ultrasonography results consistent with CAT Patients undergoing LT4 treatment Normal (or almost normal) levels of triiodothyronine (T3), thyroxine (T4), free T4 and thyrotropin (TSH)  Use of immunosuppressants, immunostimulants, or other drugs that could interfere with the production, metabolism and transport of thyroid hormones CAT with normal thyroid function CAT with subclinical hypothyroidism Thyroid nodules Hypothyroidism stemming from post-partum thyroiditis (up to 18 months after gestation) History of Graves' disease Thyrotropin receptor antibody (TRAb) detectable Prior treatment with radioiodine Tracheal stenosis Pregnancy
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 14.0-999.0,  Hypothyroidism Hyperthyroidism Outpatients with disconnected feedback control due to the following conditions Overt primary hypothyroidism with TSH level higher than 10 mU/l and FT4 concentration below 7 pmol/L (5.4 ng/L) (Partition 1) Overt primary hyperthyroidism with TSH level below 0.1 mU/l and FT4 concentration higher than 18 pmol/L (14 ng/L) (Partition 3) All other constellations, if the patient receives substitution therapy with more 1.75 µg Levothyroxin per kg of body mass (Partition 2) System in equilibrium (e.g. unchanged substitution dose over the past six weeks)  Pituitary or hypothalamic dysfunction Severe illness that may be associated with euthyroid sick syndrome (non-thyroidal illness syndrome) Medication influencing pituitary function Pregnancy Missing consent for participation in the study
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 6.0-18.0,  Cystic Fibrosis Primary Ciliary Dyskinesia Diagnosis of Cystic Fibrosis (CF) as defined by two or more clinical features of CF and a documented sweat chloride > 60 mEq/L by quantitative pilocarpine iontophoresis test or a genotype showing two well characterized disease-causing mutations or a diagnosis of Primary Ciliary Dyskinesia (PCD) as follows: definite PCD (compatible phenotype, diagnostic abnormality of ciliary ultrastructure and/or two disease-causing gene mutations) or "probable" PCD (compatible phenotype, ciliary biopsy not diagnostic but low nasal NO (<100nl/min) with negative investigation screen for both CF and immunodeficiency Informed consent and verbal assent (as appropriate) provided by the subject's parent or legal guardian and the subject 18 years of age at enrolment and able to perform reproducible spirometry Clinically stable at enrolment (FEV > 30%, oxyhaemoglobin sats > 93%) Ability to comply with study visits and study procedures  Respiratory culture positive for non-tuberculous mycobacteria (NTM), Stenotrophomonas maltophilia, Aspergillus fumigatus, Burkholderia cepacia complex, or Pseudomonas aeruginosa within past year Use of intravenous antibiotics or oral quinolones within previous 14 days Use of inhaled antibiotics within the previous 28 days Pneumothorax or haemoptysis
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 5.0-84.0,  Smoke Inhalation Injury Burns Child is at least 5 years of age and has not yet had his/her thirteenth birthday (for Studies # 1, 2, and 5) Subject (and child's caretaker for Studies #1, 2, and 5) speak English (2000 Census data indicate that less than 5% of the population older than five years of age in Franklin County, Ohio [where the study is located] speaks English less than "very well") Subject/family is able to be contacted by telephone (to obtain pre-study information and to remind the family about the study appointment and confirm that the child is in a normal state of health on day of study) For adult study arms: Study 3: Subjects are 20-49 years of age; Study 4: Subjects are 60-84 years of age  Subject has a clinical diagnosis that may affect sleep, arousal or ability to perform the escape procedure Subject has a hearing impairment Subject is taking medication that may affect sleep, arousal, or ability to perform the escape procedure Subject has an acute illness at the time of the sleep study. The target population for Study 3 consists of adults 20-49 years of age, who have not yet had his/her fiftieth birthday. Adult participants must not have a clinical diagnosis that may affect sleep, arousal or ability to perform the simulated escape procedure. He/she must not have a hearing impairment; not be taking medication that may affect sleep, arousal, or ability to perform the escape procedure; and not have an acute illness at the time of the sleep study. The adult must speak English and be able to be contacted by telephone (to obtain pre-study information and to remind the participant about the study appointment and confirm that he/she is in a normal state of health on the day of the study). The target population for Study 4 consists of older adults 60-84 years of age, who have not yet had his/her eighty-fifth birthday. The older adult must not have a clinical diagnosis that may affect sleep, arousal or ability to perform the escape; not have a hearing impairment; and not be taking medication that may affect sleep, arousal, or ability to perform the simulated escape procedure. The older adult must not have an acute illness at the time of the sleep study. The older adult must speak English and be able to be contacted by telephone (to obtain pre-study information and to remind the participant about the study appointment and confirm that he/she is in a normal state of health on the day of the study). The target population for Study 5 is the same as that for Studies 1 and 2
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 16.0-60.0,  Graves' Disease Graves' disease patients. Healthy people  Pregnancy. <16 years old or > 60 years old
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 30.0-85.0,  Heart Failure Diabetes ejection fraction at or lower than 45% type 2 diabetes  known s-creatinine >220mM known S-alanine aminotransferase >3 times normal upper limit other disabilitating conditions pregnancy insulin treatment
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 35.0-60.0,  Hypothyroidism Recently diagnosed hypothyroid subject (either during the period, or within the 6 previous months) for whom, data related to the diagnosis is available if the diagnosis was not carried out initially by the investigating doctor Subject, who has given his/her oral consent for participation  Subject included in clinical trial or having participated in a clinical trial during the last 3 months Subject presenting a major and objectifiable risk of not being able to follow-up until the next TSH level (moving, problems encountered during another study, pathology affecting the vital prognosis in the short-term) All contraindications to Lévothyrox
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Mild Cognitive Impairment female BMI 18.5-25kg/m2 aged 18-45 years regular breakfast eaters regular menstrual cycle healthy  Significant gastrointestinal disease, gastrointestinal surgery, diabetes or any other significant major medical morbidity History of significant eating disorder (anorexia, bulimia) Habitual dietary protein intake >20% of total energy intake pregnancy or breast feeding anaemia (Hb <11.5g/dL) random blood glucose concentration >8mmol/l no medication use other than contraception significant weight loss/gain (>14lb in previous 3 months)
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.692-0.712,  Infant, Newborn Infant, Low Birth Weight Infant, Small for Gestational Age Infant, Premature Bronchopulmonary Dysplasia (BPD) Infant with birthweight 401-1500 grams Alive at 36+1 week corrected age On supplemental oxygen as follows A. Infants receiving oxygen by hood at rest A1. Oxygen by hood <27% with majority* of saturations ≥ 90% in prior 24 hours A2. Oxygen by hood 27-30% with majority* of saturations ≥ 96% in prior 24 hours B. Infants receiving oxygen by nasal cannula at restΔ B1. Oxygen by nasal cannula <27% oxygen and majority* of saturations ≥90% in prior 24 hours B2. Oxygen by nasal cannula 27-30% oxygen and majority* saturations ≥96% on prior 24 hours C. Infants receiving room air by nasal cannula at ANY liter per minute (lpm) flow  Need for mechanical ventilation or continuous positive airway pressure (CPAP) Oxygen by hood >30% Oxygen by nasal cannula >30% effective oxygen
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-55.0,  Breast Cancer Premenopausal women 55 years of age or younger with regular menstrual cycles (at least four cycles in the last six months). Women with fewer than 4 menses in the last 6 months or who have had a hysterectomy with ovaries intact will be considered premenopausal if FSH level < 20. 2. Women with breast density ≥ 25% (scattered fibroglandular densities or greater) are eligible. 3. Prior Treatment 1. Patients who are currently receiving hormone replacement therapy (estrogen or progesterone); or are taking tamoxifen or raloxifene are not eligible. Women who have taken these medications must have stopped for at least 4 months prior to study entry. Topical estrogen (eg, transdermal patches and vaginal estrogens) is allowed. 2. Patients who are currently using hormonal contraception, should be taking it for at least 4 months prior to study entry. 4. Vitamin D Use 1. Patients who are taking regular vitamin D supplementation (above 400 IUs daily) and refuse or are unable to stop use are not eligible. Women who agree to stop will need to do so for at least 6 months prior to registration. 2. Patients may not start vitamin D supplementation after registration (regardless of results of vitamin D testing) but they may continue vitamin D if they are already taking 400 IUs daily or less and have been taking vitamin D for at least 6 months prior to baseline mammogram. 5. Patients with a history of breast cancer (including DCIS) or ovarian cancer are not eligible. 6. Patients with a history of breast implants or breast reduction are not eligible. 7. Patients with two or more bone fractures in the past five years are not eligible. 8. Patients with a diagnosis of osteoporosis with physician recommendation for treatment of low bone mass are not eligible. 9. Patients known to have hyperparathyroid disease or other serious disturbances of calcium metabolism requiring intervention in the past 5 years are not eligible. 10. Patients with a history of kidney stones (unless documented not to have been a calcium stone) are not eligible. 11. Patients participating in a concurrent breast cancer chemoprevention trial are not eligible. 12. Required initial laboratory values Calcium < 10.5 mg/dL
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 10.0-17.0,  Obesity Weight Gain Psychotropic Induced Weight Gain Children aged 10-17 2. Currently prescribed one of the following psychotropic medications: Haloperidol, perphenazine, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, thioridazine, chlorprothixene, loxapine, mesoridazine, thiothixene or trifluoperazine. 3. Documented weight gain while on prescribed medications 4. Either >5% weight increase from the start of medication through 3 months on, or crossing into the 95th percentile for BMI, or crossing into the 85-95th percentile plus one obesity related complication. 5. Children aged 10-17 years old with BMI >95th percentile and fasting insulin level>21.7U/L not currently on psychotropic medications  History of liver disease 2. History of kidney disease 3. Abnormal creatinine 4. Abnormal liver function blood levels -
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Healthy Male Subjects Male Age range of 18-60 years BMI between 18.5 and 28 Medication-free Capable of providing informed consent Non smoking for a minimum of one year  Meets DSM-IV for any Axis I disorder (past or present) Global assessment of functioning (DSM IV TR) less than 50 Age less than 18 or greater than 60 BMI lower than 18.5 or higher than 28 Any history of Alcohol or substance dependence or abuse according to DSM-IV (except for caffeine dependence) Any medical condition which in the opinion of the investigator may have an effect on mood symptoms Any individual who has a current mood disturbance (as defined by DSM-IV-R criteria) Use of cigarettes or other nicotine-containing products Allergy or other contraindication to uridine Individuals unable to comply with instructions or procedures of study
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-18.0,  Graves' Disease A diagnosis of GD based on initial laboratory studies showing a suppressed TSH (i.e. <0.01); high total T3, high total T4 and/or free T4 level; an elevated thyroid stimulating immunoglobulin (TSI) titer; increased and diffuse uptake of 123I, 131I, or 99Tc in the thyroid gland. 2. Age <18 years at the time of GD disease diagnosis. 3. Non-smoking parents  > 18 years. 2. Smoking parents
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Sclerosis Hashimoto Thyroiditis Thyroid Nodules Clinical diagnosis of systemic sclerosis  non
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 20.0-34.0,  Type 2 Diabetes Mellitus You are one of a sibling pair with the same mother and father, and your mother had diabetes (gestational or type 2) while she was pregnant with the younger sibling but not the older sibling Your sibling is willing to participate in the study You are between the ages of 20 and 34 years (inclusive) Your body mass index is between 20 and 29 Kg/m2 inclusive (this is a number calculated for your height and weight and indicates that you are either normal weight or overweight, but not obese) You are healthy as assessed by medical history and standard physical examination You are weight stable (your body weight has not changed .6.5 lbs over the last 3 months) You do not smoke You provide written informed consent to participate in the study You are willing to stay overnight one time at the Pennington Center You have low physical activity (< 100 min of exercise per week)  You were born prematurely (<37 weeks of pregnancy) You are currently taking medication that may influence your body weight or metabolism You have heart disease, lung disease, liver disease, blood disease, kidney disease, type 1 or 2 diabetes, or any other disease that in the opinion of the doctor might make you ineligible
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Obesity Metabolic Syndrome Schizophrenia phase 1 fulfilled DSM-IV of schizophrenia or schizoaffective disorder 65 year of age receiving clozapine for at least 6 months. phase 2 are those in phase 1 and met the following overweight and obese (BMI ≧ 24) one or more metabolic dysregulation, such as abdominal obesity (waist circumference > 90 cm, in men and > 80 cm, in women fasting hypertriglyceridemia, (≥ 150 mg/dL) low fasting HDL levels (< 40 mg/dL in men and < 50 mg/dL in women) high blood pressure (≥ 130/ ≥ 85 mm Hg or current treatment with antihypertensive medication). The  are the following current use of hypoglycemic or hypolipidemic agents FPG levels ≥ 126 mg/dL women who are pregnant known allergy or contraindicated to metformin (including Creatine>1.4 ng/dl abnormal liver function test; chronic cardiopulmonary insufficiency) phase 2 current use of hypoglycemic or hypolipidemic agents FPG levels ≥ 126 mg/dL women who are pregnant known allergy or contraindicated to metformin (including Creatine>1.4 ng/dl abnormal liver function test